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NAMPT (Nicotinamide phosphoribosyltransferase) catalyses the rate-limiting step in the NAD biosynthesis from nicotinamide and thereby regulates the activity of NAD-dependent 
enzymes. Cancer cells are highly dependent on NAD for energy and DNA repair processes and are assumed to be more susceptible to an inhibition of NAD synthesis than non-
transformed cells. We aimed to investigate whether or not inhibition of NAMPT with its specific inhibitor FK866 can sensitize leukemia cells for chemotherapeutic agents. 
NAMPT protein abundance, enzymatic activity and NAD concentrations were significantly higher in Jurkat and Molt-4 leukemia cell lines compared to normal peripheral blood 
mononuclear cells. Combination of eto- poside and FK866 caused increased cell death in leukemia cell lines compared to etoposide alone. Etoposide decreased protein abundance 
of NAD-dependent deacetylases SIRTUIN1. After combining etoposide and FK866 treatment SIRTUIN2 was further decreased and accumulation and acetylation of the downstream 
target p53 was further enhanced in MOLT4 cells. Concomitantly, protein abundance of p21 and cleaved BAX was increased. 










Leukemia is the most common cancer diagnosed in children and represents approximately 30% of  cancer diagnoses among  children younger than 15 years 
[1]. The main treatment for childhood leukemia is chemotherapy [2]. Children with high-risk leukemia or relapse gen- erally receive more intense and aggressive 
chemotherapy, e.g. treat- ment with etoposide [3,4]. Although chemotherapy is successful in up to 90% of pediatric patients with acute lymphoblastic leukemia, 
the toxicity of chemotherapy is a common cause of morbidity and mortality in children during treatment and later in life [5]. New strategies to reduce doses of 
chemotherapeutics are therefore urgently needed. 
Cancer cells are characterized by metabolic adaptations such as a high nicotinamide adenine dinucleotide (NAD) turnover rate due to increased proliferation, 
DNA repair and metabolism [6,7]. Nicotina- mide phosphoribosyltransferase (NAMPT) is the key enzyme of the NAD salvage pathway from nicotinamide 
and thus a regulator of the intracellular NAD pool. NAMPT was shown to be overexpressed in different types of cancer, among them hematologic malignancies 
such as leukemia [8] and lymphomas [9]. Given that, NAMPT may be crucial for maintaining cellular NAD levels in cancer cells to facilitate cancer proliferation 
and survival. It is therefore a potential therapeutic target for the treatment of cancer. 
SIRTUIN1 (SIRT1) and SIRT2 are NAD-dependent enzymes that are overexpressed in leukemia and could play a causal role in leukemia development Dan 
et al., 2012; Kozako et al., 2012; Wang et al., 2011b. Furthermore, these two central SIRTs play an important role in tumor metabolism by deacetylating p53 
and therefore regulating apoptosis [10,11]. 
FK866 (APO866) is a specific inhibitor for NAMPT [12]. Treatment with FK866 reduced intracellular NAD levels leading to apoptosis and reduced cell 
proliferation in leukemia cell lines with functional tumor suppressor p53. This effect was mediated by increased acetylation of p53 at lysine 382 with 
subsequently increased expression of p21 and BAX. In contrast, leukemia cell lines containing nonfunctional p53 were relatively unaffected by FK866 treatment 
[13].  Furthermore,  FK866 had minor toxic effects on normal hematopoietic progenitor cells [14]. Although FK866 was relatively well tolerated in humans and 
advanced to phase II clinical trials, it did not demonstrate sufficient tumor se- lectivity to achieve clinical success as single agent [15]. 
However, combining NAD depletion with chemotherapeutic agents might enhance their therapeutic efficacy [13]. In neuroblastoma cells, the effects of etoposide 
on DNA damage were potentiated by FK866 treatment, whereas the effect of FK866 on cytosolic NAD depletion was potentiated by etoposide [16]. In 
neuroendocrine tumors, the NAMPT inhibitor GMX1778 enhanced the efficacy of 177Lu-DOTATATE treat- ment and induced a prolonged antitumor response 
[17]. 
The aim of this study is to test the hypothesis that NAMPT inhibition using the specific inhibitor FK866 makes leukemia cells more suscep- tible for 
chemotherapeutic agents and to elucidate underlying signal- ling pathways. 
 




Cell culture media and supplements were obtained from PAA (Cölbe, Germany) or Invitrogen (Karlsruhe, Germany). FK866 and ni- cotinamide mononucleotide 
(NMN) were obtained from Sigma Aldrich (Munich, Germany). Etoposide was purchased from Merck Millipore (Darmstadt, Germany). Primary antibodies were 
obtained from Cell Signaling (CST, Beverly, MA, USA) and Millipore. Secondary antibodies were purchased from DAKO (Hamburg, Germany). 
 
2.2. Cell culture 
 
Jurkat and Molt-4 T-ALL cell lines were purchased from Leibniz Institute DSMZ (German Collection of Microorganisms and Cell Cultures). The cell 
lines were cultured in RPMI 1640 medium with 2 mmol/L glutamine and 10% fetal bovine serum (FBS) for Jurkat cells and 20% FBS for Molt-4 cells. All cells 
were grown at 37 °C in a hu- midified atmosphere of 95% air and 5% CO2. Cell number was mea- sured using a hemacytometer after trypan blue staining. 
 
2.3. PBMC isolation 
 
Peripheral blood mononuclear cells (PBMCs) were isolated from anonymised blood buffy coats of healthy donors purchased from the University Hospital 
Leipzig Blood Bank. Buffy coats were diluted in lysis buffer (155 mM NH4Cl; 10 mM KHCO3; 0.1 mM Na-EDTA; pH 7.29), gently mixed and kept on ice for 
10 min. After centrifugation, the supernatant was removed carefully and the process was repeated until the pellet appeared clear. 
 
2.4. Cell treatments 
 
Etoposide was dissolved in DMSO to generate a stock solution of 
42.5 mM. FK866 was dissolved in DMSO to create a stock solution of 10 mM. NMN was dissolved in the appropriate medium for a stock so- lution of 100 mM. 
Jurkat and Molt-4 cells were treated with the in- dicated concentrations of etoposide, indicated concentrations of FK866 or NMN [500 μM] either alone or in 
combination for 24 h. 
 
2.5. Measurement of cell viability and cell death 
 
To investigate the effects of the chemotherapeutic agents on pro- liferation and cell viability, Cell Proliferation Reagent WST-1 (Roche, Grenzach-Wyhlen, 
Germany) was used according to manufacturer’s instructions. 40,000 cells/well were seeded in a 96-well plate and cultured as described above. 
To evaluate the effects of etoposide the number of dead cells was measured by flow cytometry using propidium iodide (PI) (Calbiochem, Dan Diego, CA, USA). 
800,000 cells/well were seeded in a 6-well plate and cultured as described above. Cells were harvested and washed with ice-cold PBS. The cell pellet was re-suspended 
in 100 μL of PBS with 0.5% FBS. Cell suspension was transferred into round bottom tubes. 2 μL of PI were added to the cell suspension, followed by gentle 
vor- texing. Samples were incubated for 10 min on ice in darkness and analysed using a Beckton-Dickinson FACS LSRII. For each sample, 10,000 cells 
were counted. PI+  cells were considered dead. 
 
2.6. Protein extraction and Western blot analyses 
 
Cells were lysed in modified RIPA buffer as previously described [18]. Protein concentration was determined using Pierce BCA protein assay (Thermo 
Scientific) and equal amounts of protein were separated by SDS–PAGE and transferred to nitrocellulose membranes using a semi-dry transfer apparatus. Next, 
membranes were blocked in 5% non- fat dry milk in TBS buffer containing 0.1% Tween 20. Primary anti- bodies used for immunoblotting included anti-
NAMPT (clone OMNI 
379) (Cayman Chemical, Ann Arbor, MI, USA), anti-Caspase-3, anti- PARP, anti-SIRT1, anti-SIRT2, anti-Ac-p53, anti-p53, anti-p21, anti-Bax (Cell Signaling, 




Germany). Detection of proteins was carried out using Luminata Classico Western HRP Substrate (Merck Millipore) or Amersham ECL Prime Western Blotting 
Detection Reagent (GE Healthcare). 
 
2.7. NAMPT enzymatic activity 
 
NAMPT activity was measured by the conversion of 14C-labeled nicotinamide to 14C-NMN using a method previously described [19]. Radioactivity of 
14C-NMN was quantified in a liquid scintillation counter (Wallac 1409 DSA, PerkinElmer). 1 × 106 cells were seeded in dishes (152 cm2) and cultured as 
described above. NAMPT activity (counts per minute, cpm) was normalized to total protein concentration as measured by BCA protein assay. 
 
2.8. NAD measurement 
 
Concentrations of total NAD from whole-cell extracts were quanti- fied by HPLC analysis by reversed-phase HPLC using a Chromaster Purospher STAR 
RP-18 endcapped 3 μm Hibar RT 150-3 HPLC column (Merck). 800,000 cells/well were seeded in a 6-well plate and cultured as described above. Cells were 
harvested and pellet was re-suspended in 100 μL 1 M perchloric acid. After a 10-min incubation period on ice samples were centrifuged and the supernatant was 
neutralized with 3 M potassium carbonate. After repeated centrifugation samples were loaded onto the column as previously described [18]. 
The cell pellet of each sample was resuspended in 100 μL 2% SDS, 
shaken for 10 min at 99 °C and centrifuged for 5 min at 20,000g and then used for protein determination (BCA Assay, Pierce Thermo Scientific). The NAD 
concentration of each sample was referred to the corresponding total protein amount of the sample. 
 
2.9. Statistical analyses 
 
Data are presented as mean ± SEM. Data were analysed for sta- tistical significance by either unpaired Student’s t-test or one-way analysis of variance 
(ANOVA) followed by Bonferroni post hoc test. All analyses were performed using GraphPad Prism 6 software (GraphPad Software, Inc., San Diego, CA, USA). 






Fig. 1. NAMPT protein abundance, activity and 
NAD levels are higher in leukemia cell lines. 
NAMPT protein abundance (A), NAMPT activity 
(B) and NAD levels (C) were measured in PBMCs, 
Jurkat cells and Molt-4 cells. Western Blots show 
results of 3 independent experiments and lanes 
were analyzed densito- metrically.  Data   are   
represented   as mean ± SEM and statistical 
analysis was per- formed using one-way ANOVA 
and Bonferroni post hoc test (*p < 0.05 compared 



















3.1. Cancer cell lines have higher NAMPT protein abundance and 
activity 
 
We compared the leukemia cell lines Jurkat (mutated p53) and Molt-
4 (wildtype p53) [20] with peripheral blood mononuclear cells (PBMCs) 
from healthy donors in regard to NAMPT protein abundance, NAMPT 
activity and NAD levels. Jurkat and Molt-4 cancer cell lines showed higher 
NAMPT protein abundance (25-fold in Jurkat cells, 21- fold in Molt-4 cells) 
compared to PBMCs (Fig. 1A). Furthermore, NAMPT activity (94.1 ± 18.2 
cpm/μg total protein x h in Jurkat cells; 
24.6 ± 2.6 cpm/μg total protein x h in Molt-4 cells) (Fig. 1B) and NAD 
levels were elevated in cancer cell lines (9.5 ± 1.6 μmol NAD/g pro- tein in 
Jurkat cells, 0.9 ± 0.2 μmol NAD/g protein in Molt-4 cells) compared to 
PBMCs (Fig. 1C). 
 
3.2. FK866 decreases viability, NAMPT activity and NAD levels 
 
We tested the sensitivity of Jurkat and Molt-4 cell lines to inhibition of 
NAMPT using the specific inhibitor FK866. Incubation of cells with 
FK866[10 nM] for 24 h reduced viability (−59.5 ± 3.3% in Jurkat cells, 
−46.1 ± 4.6% in Molt-4 cells) (Fig. 2A,B)(Supporting Informa- tion 1 
A,B). NAMPT activity was decreased in both cells lines sig- nificantly at 
a concentration of 1 nM FK866 and was almost completely blocked after using 
a concentration of 10 nM FK866 in both cell lines. (Fig. 2C,D).NAD 
concentrations were lowered (by 80% in Jurkat and Molt-4 cells) (Fig. 2 
E,F)(Supporting Information 1C,D) compared to control cells. The enzymatic 
product of NAMPT, NMN [500 μM], was able to rescue viability (Fig. 2A,B) 
and NAD levels (Fig. 2E,F) of both Jurkat and Molt-4 cells, whereas it had 
no effect alone. 
 
3.3. FK866 increases etoposide-induced cell death 
 
To evaluate whether NAMPT inhibition could enhance the effects of 
chemotherapeutic agents, Jurkat and Molt-4 cells were incubated with the 
anti-leukemia drugs etoposide (eto), methotrexate (mtx) and dox- orubicin 
(doxo) alone or in combination with FK866 for 24 h. Etoposide was able to 
induce cell death (4.0-fold ± 0.6 [10 μM]) in Jurkat cells compared to 
control cells (Fig. 3A). Molt-4 cells were more sensitive to etoposide, which 
induced 5.6-fold ± 1.0 [5 μM] cell death (Fig. 3B). FK866 treatment alone 
did not induce cell death in both cell lines after 24 h. However, the 
combination of etoposide and FK866 increased the number of dead cells 
compared to etoposide treatment alone (5.4- fold ± 1.4 in Jurkat cells, 1.8-
fold ± 0.1 in Molt-4 cells) (Fig. 3A,B). NMN was able to reverse the 
FK866-induced effects. Methotrexate (mtx) and doxorubicin (doxo) only 
induced cell death in Molt-4 cells (+17.8% ± 2.0% and 65.8% ± 8.2%, 
respectively). Combining mtx or doxo with FK866 did not increase cell death 
in Jurkat or Molt-4 cells (Supporting Information 2). 
Etoposide treatment induced cleavage and activation of caspase-3 and its 
downstream target poly (ADP-ribose) polymerase (PARP)-1, but this cleavage 
was not further increased by the addition of FK866 to etoposide (Fig. 3C, 
D). A combination of etoposide and FK866 did not alter cell cycle distribution 
after 24 h (Supporting Information 3). 
 
3.4. Etoposide-induced downregulation of SIRT2 is enhanced by NAD 
depletion 
 
Next, we  aimed to  determine whether  the increased  cell death provoked 
by etoposide and FK866 co-treatment could be caused by a further decrease 
in NAD levels. The NAD depletion induced by FK866 was not further 
enhanced by etoposide (Supporting Information 4). NAMPT protein 
abundance was not changed. However, etoposide treatment was able to 
decrease the amount of NAD-dependent deace- tylases SIRT1 and SIRT2 dose-
dependently in p53 wildtype Molt-4 cells. After etoposide treatment of NAD-
depleted cells SIRT2 was even further decreased (Fig. 4A). The acetylation and 
activation of the SIRT1 as well as SIRT2 target p53 was enhanced after co-
treatment of etoposide with FK866, which was associated with an increased 
abundance of its downstream target p21 (Fig. 4B). Additionally, etoposide 
treatment induced cleavage of p53 downstream target BAX which was 
further enhanced by the combination with FK866. (Fig. 4B). Jurkat cells which 
harbour a mutated p53 did not show p53 acetylation or altered levels of p21 or 




Cancer cells have a high NAD turnover rate due to their increased 
proliferation, DNA repair, cell cycle progression and metabolism [6,7]. We 
therefore tested the efficacy of NAD depletion to sensitize leukemia cells for 
chemotherapeutic treatment with the aim to provide novel treatment options 






Fig. 2. FK866 decreases viability, NAMPT activity and NAD levels. Viability (A,B), NAMPT activity (C,D) and NAD levels (E,F) were measured in Jurkat and Molt-4 cells after 
stimulation with FK866 with indicated concentrations and/or NMN [500 μM] for 24 h. Data are represented as mean ± SEM and statistical analysis was performed using unpaired 
Student’s t‐test or one-way ANOVA with Bonferroni post hoc test (*p < 0.05 compared to control; +p < 0.05 compared to FK866). 2- column fitting image. 
 
effects for patients. 
The NAD salvage enzyme NAMPT was shown to be overexpressed in 
hematologic malignancies [8,9,21]. We could confirm these findings and 
furthermore showed that basal NAMPT activity and NAD levels were also 
increased in leukemia cells in comparison to PBMCs from healthy volunteers. 
We used FK866 (APO866) to specifically target NAMPT [12]. Thakur 
et al. proposed that leukemia cell lines containing nonfunc- tional p53 were 
relatively unaffected by FK866 [13], whereas FK866 was able to induce 
cell death in p53-deficient hepatocarcinoma cells [22]. In our study, FK866 
decreased viability, NAMPT activity and consequently depleted NAD levels 
in both p53 mutated (Jurkat) and p53 wildtype (Molt-4) cells. 
Given the influence of NAD depletion on regulators of cellular survival 
and stress responses, such as PARPs and sirtuins, we postulated that FK866 
could synergize with chemotherapeutic agents that target the same pathways. 
Travelli et al. showed that the etoposide-specific effect of inducing DNA 
damage was potentiated by FK866 [16]. Con- trary to their findings, however, 
we did not see an additive effect on total cellular NAD depletion (Supporting 
information 4). We could show  that  inhibition  of  NAMPT  with  FK866  
in  combination  with 
etoposide led to increased cell death compared to etoposide alone. In- 
terestingly, this effect was not mediated by the caspase cascade. This result 
stands in contrast to a study performed in HEK293 cells, where a knockdown 
of NAMPT made cells more sensitive to etoposide treatment and levels of  
cleaved caspase-3 were  increased, whereas  the over- expression of NAMPT 
led to a resistance of cells to etoposide and re- duced levels of cleaved caspase 
3 [23]. However, apoptosis, autophagy as well as necrosis were proposed as 
mechanisms of cell death induction by FK866 [6,14,24] or combination 
treatments [16,21,25]. The lack of apoptosis induction by FK866 could also 
be explained by the shorter treatment period we used compared to other 
studies [13,22]. 
SIRT1 and SIRT2 are overexpressed in leukemia cells, both are in- volved 
in disease development and drug resistance [26–28]. In our study, 
combining etoposide with FK866 decreased SIRT2 protein abundance in 
Molt-4 cells more than etoposide alone. Possible me- chanisms leading to 
selective SIRT2 depletion could involve the up regulation of microRNAs 
targeting SIRT2 [29], as has been reported for the effects of etoposide on 
SIRT1 protein [30]. 
P53 is a target of both SIRT1 and SIRT2 [10,11]. Blocking SIRT1 
activity was shown to increase acetylation of p53 at lysine 382 in combination 






Fig. 3. FK866 increases etoposide-induced cell death. Jurkat and Molt-4 cells were stimulated with etoposide [0.1, 1, 5 or 10 μM] alone or in combination with FK866 [10 nM] 
and/or NMN [500 μM] for 24 h. Cell death was measured by flow cytometry using propidium iodide (A,B). Cleaved and full-lenght caspase-3 and 
PARP-1 protein abundance was detected by Western blot analysis (C,D). Western Blots show results of at least 3 independent experiments, GAPDH was used as loading control 
and lanes were analyzed densitometrically. Data are represented as mean ± SEM and statistical analysis was performed using one-way ANOVA and Bonferroni post hoc test (*p < 






Fig. 4. Etoposide-induced downregulation of SIRT2 is enhanced by NAD depletion. Molt-4 cells were stimulated with etoposide [5 μM] alone or in combination with FK866 [10 nM] 
and/or NMN [500 μM] for 24 h. NAMPT, SIRT1 and SIRT2 (A), acetyl-p53, p53, p21 and BAX (B) protein abundance was analysed by Western blot. 
Western Blots show results of at least 3 independent experiments and lanes were analyzed densitometrically. GAPDH was used as loading control. Data are re- presented as mean 
± SEM and statistical analysis was performed using one-way ANOVA and Bonferroni post hoc test (*p < 0.05 compared to control; +p < 0.05 compared to FK866 alone; #p < 
0.05 compared to etoposide [eto]; $ compared to eto + FK866). 2-column fitting image. 
 
cell line Molt-4, we found an accumulation of p53 after treatment with 
etoposide [33]. Furthermore, the combined effect of FK866 and eto- poside 
on SIRT2 was mirrored by an even stronger induction of p53 acetylation,  
higher  expression  of  p53  downstream  target  p21  and 
cleavage of BAX. The cleavage of BAX during apoptosis was shown to 
increase the intrinsic cytotoxic properties of this proapoptotic factor [34]. 
This activation of p53-p21 signalling, as well as the increased cell death  seen  





reversible by supplementation with NMN, which confirmed the effects to be 
specific for NAD depletion [35–37]. In Jurkat cells, which harbour a mutated 
p53, we did not detect p53 dependent changes in p21 or cleaved bax and no 
reduction in SIRT2 levels. A failure of p21 induction upon etoposide exposure 
has been shown before [38]. Potentially, cell death in Jurkat cells could be 
induced via c-Myc. SIRT2 inhibits c-Myc ubiquitination and degradation 
supporting tumorigenesis. Vice versa, reduced SIRT2 activity due to NAD 
depletion leads to cell death by c- Myc ubiquitination and degradation [39]. 
We therefore conclude that there are at least two pathways mediating the 
increased cell death seen upon combined treatment with etoposide and FK866 
and that p53 is dispensable for cell death induction in this scenario. 
 
5. Conclusion 
Combined treatment with the NAMPT inhibitor FK866 potentiates the 
effects of chemotherapeutic agent etoposide and leads to a strong induction 
of cell death in vitro, via downregulation of SIRT2 and acti- vation of the p53-
p21 pathway in the p53 competent Molt-4 cells. Targeting NAD salvage may 
be a useful strategy for chemo-sensitisation with the possibility to increase the 
efficacy of chemotherapeutic agents in the treatment of childhood leukemia. 
Additionally, SIRT2 inhibitors may represent interesting therapeutic options 
for p53 wildtype leu- kemia. 
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